Find Print
0 Find synonyms

Find synonyms Find exact match

What's new in obstetrics and gynecology
Official reprint from UpToDate® ©2017 UpToDate®
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
What's new in obstetrics and gynecology
All topics are updated as new evidence becomes available and our peer review process is complete.
Literature review current through: Feb 2017. | This topic last updated: Mar 20, 2017.

The following represent additions to UpToDate from the past six months that were considered by the editors and authors to be of particular interest. The most recent What's New entries are at the top of each subsection.


New classification and guidance regarding suboptimally dated pregnancy (March 2017)

The American College of Obstetricians and Gynecologists now classifies pregnancies as "suboptimally dated" in the absence of an ultrasound examination before 220/7ths weeks of gestation [1]. Because fetal biometry after 22 weeks is not sufficiently accurate to change menstrual dating without correlative sonographic follow-up, serial examinations three to four weeks apart are advised in these cases to assess growth over time. Normal interval growth supports the sonographic estimate of gestational age, while suboptimal or accelerated interval growth suggests that the gestational age may be further along or less advanced than predicted by ultrasound. (See "Prenatal assessment of gestational age and estimated date of delivery", section on 'Assigning the estimated date of delivery'.)

Recommended immunization schedule—United States, 2017 (March 2017)

The Advisory Committee on Immunization Practices has released the 2017 recommended immunization schedule for children and adolescents in the United States [2,3]. New recommendations include the following:

All infants should now receive monovalent hepatitis B vaccine within 24 hours of birth; earlier recommendations allowed some infants born to hepatitis B surface antigen-negative mothers to receive the vaccine after discharge. (See "Hepatitis B virus immunization in infants, children, and adolescents", section on 'Mother's HBsAg status unknown, birth weight ≥2 kg'.)

When administered during pregnancy, the tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine should be given as early as possible between 27 and 36 weeks of gestation. (See "Immunizations during pregnancy", section on 'Tetanus, diphtheria, and pertussis vaccination'.)

For individuals receiving the meningococcal serogroup B vaccine MenBFHbp (Trumenba), two doses are recommended for healthy adolescents and young adults who are not at increased risk for meningococcal disease. Three doses are recommended for individuals ≥10 years of age at increased risk for meningococcal disease and for use during serogroup B meningococcal disease outbreaks (table 1). Previously, three doses were recommended for all recipients. The dosing frequency and interval for the other serogroup B vaccine, MenB-4C (Bexsero), have not changed. (See "Meningococcal vaccines", section on 'Serogroup B meningococcus vaccines'.)

Aspirin for prevention of preeclampsia (February 2017)

Low-dose aspirin therapy during pregnancy reduces the occurrence of preeclampsia in high-risk women, but questions remain about optimum dosing and timing. In one recent meta-analysis, the optimum aspirin dose appeared to be 100 to 150 mg, with favorable effects limited to initiation before 16 weeks of gestation [4]. In another recent meta-analysis with a different design, aspirin was similarly effective whether initiated before or after 16 weeks of gestation; optimum dosing was not assessed [5]. For women at high risk of developing preeclampsia, we continue to suggest initiating aspirin 81 mg daily at the end of the first trimester because this dose is readily available and early initiation is both safe and effective. If aspirin is not initiated at this time, initiation after 16 weeks, but before symptoms develop, also appears to be effective. (See "Preeclampsia: Prevention", section on 'Meta-analysis'.)

Maternal fish oil supplementation and asthma in offspring (February 2017)

Maternal supplementation with fish oil, which consists of two n-3 long chain polyunsaturated fatty acids (docosahexaenoic acid [DHA]) and eicosapentaenoic acid [EPA]), has been proposed to improve a variety of pregnancy outcomes. In a placebo-controlled randomized trial of third-trimester maternal supplementation with fish oil 2.4 grams daily (55 percent EPA and 37 percent DHA), supplementation resulted in a 7 percent reduction in the absolute risk of persistent wheeze or asthma in offspring followed to age three to five years [6]. Because of limitations in the design of this trial, UpToDate does not advise routine supplementation with this dose of fish oil, but continues to recommend that all pregnant women achieve DHA intake of at least 200 to 300 mg/day. (See "Fish consumption and omega-3 long-chain polyunsaturated fatty acid supplementation during pregnancy", section on 'Atopic and allergic disease, asthma'.)

Folic acid supplementation for prevention of neural tube defects (February 2017)

Folic acid supplementation and food fortification have reduced the incidence of neural tube defects (NTDs). A 2017 systematic review by the US Preventive Services Task Force (USPSTF) noted that post-food fortification studies of folic acid supplementation have not demonstrated a protective association [7], suggesting that current levels of food fortification may be sufficient to prevent most folate-sensitive NTDs. However, the USPSTF also reaffirmed its 2009 recommendation that all women of reproductive age planning or capable of pregnancy take a supplement containing 0.4 to 0.8 mg of folic acid daily to reduce their risk of having a child with a NTD [8]. Given the limitations of the post-food fortification studies, we agree with this recommendation. (See "Folic acid supplementation in pregnancy", section on 'Folic acid supplements' and "Folic acid supplementation in pregnancy", section on 'Food fortification'.)

United States guidelines for fish consumption during pregnancy and lactation (February 2017)

Fish may be contaminated by environmental pollutants, such as methylmercury, which can cause fetal neurologic problems. The US Food and Drug Administration and Environmental Protection Agency released updated recommendations about fish consumption for women who are pregnant or nursing, or who might become pregnant [9]. Revisions include guidance on many more types of fish and recommendations for best choices versus good choices (table 2). (See "Nutrition in pregnancy", section on 'Fish consumption'.)

Delayed cord clamping (January 2017)

Delaying umbilical cord clamping for at least 30 to 60 seconds after birth in both term and preterm vigorous infants is the recommendation of an updated committee opinion by the American College of Obstetricians and Gynecologists (ACOG) [10]. Previously, ACOG had recommended individualizing the timing of cord clamping in term infants. Although the optimal amount of time before cord clamping has not been studied extensively, we believe data support a minimum duration of delay of at least one minute in term births and 30 seconds in preterm births. (See "Management of normal labor and delivery", section on 'Cord clamping'.)

Risk of birth defects with Zika virus infection during pregnancy (January 2017)

The risk of birth defects resulting from in utero exposure to Zika virus was 6 and 42 percent in two recent reports [11,12]. The wide range likely reflects differences in study design, populations studied, maternal Zika case definition, and the range of clinical abnormalities included. The most common fetal/newborn findings in these reports were abnormal brain imaging, microcephaly, small size for gestational age, and abnormal neurologic examination. The greatest risk of serious sequelae in offspring appeared to be with first or second trimester infection, but serious sequelae also occurred with third trimester infection. (See "Zika virus infection: Evaluation and management of pregnant women", section on 'Risk of vertical transmission and anomalies' and "Congenital Zika virus infection: Clinical features, evaluation, and management of the neonate", section on 'Clinical findings'.)

Trends in marijuana use during pregnancy (December 2016)

The impact of recent laws legalizing marijuana for medical and recreational use on use by pregnant women is unknown. In a survey of marijuana use among reproductive-aged women, use of marijuana in the past month by pregnant women increased 62 percent between 2002 and 2014 (from 2.4 to 3.9 percent) and was highest among women aged 18 to 25 years [13]. As there are multiple concerns about the neurodevelopmental impact of marijuana on the developing fetus, abstinence during pregnancy is advised. (See "Overview of substance misuse in pregnant women", section on 'Marijuana'.)

FDA issues warning about anesthesia for pregnant patients and children under three years of age (December 2016)

The US Food and Drug Administration has warned about potential negative effects on the developing brain from administration of anesthetics and sedatives to pregnant women and children under age three, especially for repeated exposures or procedures lasting more than three hours [14]. However, the degree of risk remains unclear. A single, brief exposure to anesthesia probably does not cause neurotoxicity in healthy young children. Further study is required to determine the effects of prolonged or repeated anesthetics, variability among anesthetic agents and combinations of drugs, and patient factors that may confer vulnerability to anesthetic neurotoxicity. At present, there is no compelling evidence that any specific anesthetic agent should be avoided during pregnancy or in young children, or that necessary surgery should be delayed because of concerns about neurotoxicity. (See "Management of the pregnant patient undergoing nonobstetric surgery", section on 'Fetal brain development'.)

Pattern of anomalies in congenital Zika syndrome (November 2016)

The clinical spectrum of congenital Zika syndrome (CZS) is evolving as more cases are described. A comprehensive review of the available published data identified five unique features of CZS that are rarely seen with other congenital infections: (1) severe microcephaly with partially collapsed skull, (2) thin cerebral cortices with subcortical calcifications, (3) macular scarring and focal pigmentary retinal mottling, (4) congenital contractures (arthrogryposis), and (5) marked early hypertonia [15]. Recognition of this distinctive phenotype can help clinicians identify infants with CZS and ensure appropriate etiologic evaluation and comprehensive clinical investigation. (See "Congenital Zika virus infection: Clinical features, evaluation, and management of the neonate", section on 'Clinical findings'.)

Extended versus narrow spectrum antibiotic prophylaxis for cesarean delivery (November 2016)

Use of extended versus narrow spectrum antibiotic prophylaxis for cesarean delivery is controversial. In the largest randomized trial, which was limited to women in labor or with ruptured membranes for at least four hours, the combination of azithromycin and cefazolin resulted in a 50 percent reduction in postcesarean infection compared with cefazolin alone [16]. This trial had a high proportion of obese patients and lacked comparative data on the efficacy of weight-based cefazolin dosing, which may have accounted, at least in part, for the findings. We continue to use single-dose narrow-spectrum antibiotic prophylaxis for all patients before cesarean delivery; however, others may reasonably choose to use an extended spectrum regimen in the high-risk patient population targeted by the trial. (See "Cesarean delivery: Preoperative issues".)

Closed-loop insulin pump in pregnant women with type 1 diabetes (October 2016)

A recent crossover trial in 16 pregnant women with type 1 diabetes compared use of a closed-loop insulin pump (automatic adjustment of basal insulin dose) with manual adjustment of the basal insulin [17]. The closed loop pump improved glycemic control with no difference in hypoglycemia rate, but the incidence of large for gestational age infants remained high. This technology is not readily available and, in this small trial, provided no clear pregnancy benefit. (See "Pregestational diabetes mellitus: Glycemic control during pregnancy", section on 'Types of insulin pumps'.)

Safety of magnetic resonance imaging and gadolinium in pregnancy (September 2016)

Magnetic resonance imaging (MRI) may be used for diagnostic imaging in pregnancy when ultrasound examination is inadequate; however, fetal safety has not been conclusively established. Recently, the largest study of MRI in pregnancy (over 1700 exposed and 1.4 million unexposed births) reported that first-trimester MRI was not associated with significantly increased risks for stillbirth, neonatal death, congenital anomaly, neoplasm, or vision or hearing loss in children followed up to age four years, when adjustments were made for differences between exposure groups [18]. The study also found that gadolinium exposure at any time during pregnancy was associated with an increased risk for stillbirth and neonatal death. Children exposed in utero were at increased risk for rheumatological, inflammatory, or infiltrative skin conditions, but not congenital anomalies or nephrogenic systemic fibrosis (NSF). This study is a major addition to the body of evidence supporting the safety of MRI in pregnancy when medically indicated. It also provides the first data supporting existing recommendations to avoid use of gadolinium-based contrast agents in pregnant women, when possible. (See "Diagnostic imaging procedures during pregnancy", section on 'Magnetic resonance imaging'.)


No role for routine serologic screening for genital herpes infection (December 2016)

Genital herpes, which can be caused by herpes simplex virus type 1 or 2 (HSV-1 or HSV-2), is one of the most common sexually transmitted infections, and sexual transmission can occur even in the absence of symptoms. Despite this, routine serologic screening for herpes simplex is not recommended in asymptomatic adolescents and adults due to significant limitations of available tests, as highlighted in a recent US Preventive Services Task Force statement [19]. Limitations include the low specificity and high false positive rate of serologic tests for HSV-2 and the inability of serologic tests for HSV-1 to differentiate oral from genital infection. Furthermore, there are no specific treatment interventions for asymptomatic patients, so the anxiety and disruption of personal relationships associated with a positive test outweigh any potential benefits. (See "Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection", section on 'Screening'.)

Vaginal prasterone for dyspareunia in postmenopausal women (November 2016)

In November 2016, the US Food and Drug Administration approved the use of prasterone (also known as dehydroepiandrosterone [DHEA]) for treatment of dyspareunia in women with vulvovaginal atrophy (VVA) due to menopause [20]. In an earlier randomized trial of women with VVA and moderate to severe dyspareunia, 12 weeks of daily intravaginal DHEA resulted in improved scores for pain during sexual activity and other key domains of female sexual function (desire, arousal, lubrication, orgasm, satisfaction) compared with placebo [21]. However, patients may find daily dosing more cumbersome than twice-weekly dosing with vaginal estrogen preparations. (See "Treatment of genitourinary syndrome of menopause (vulvovaginal atrophy)", section on 'Dehydroepiandrosterone (prasterone)'.)

Combination antiretroviral treatment in pregnancy (November 2016)

Combination antiretroviral treatment (ART) has become the worldwide standard of care for HIV-infected pregnant women, both for their own health and for prevention of HIV transmission to their infants. In a large randomized trial of HIV-infected pregnant women in Africa and India, antepartum ART (with one of two different protease inhibitor-based regimens) resulted in lower transmission rates compared with zidovudine plus single-dose nevirapine (0.5 versus 1.8 percent) [22]. Rates of preterm birth at <37 weeks were higher with the ART regimens than with zidovudine, but more significant prematurity (<34 weeks) and neonatal deaths were not increased. Clinicians should discuss with patients the potential risk for adverse pregnancy outcome with certain ART regimens. (See "Safety and dosing of antiretroviral medications in pregnancy", section on 'Preterm birth'.)

Long-acting reversible contraception and teenage pregnancy rates (November 2016)

In a systematic review of nine studies including nearly 27,000 adolescent and young adult women (≤25 years), the 12-month continuation rate was nearly twice as high with the intrauterine device or contraceptive implant as with other contraceptive methods (approximately 85 percent versus 40 to 50 percent) [23]. Increased contraceptive use, particularly increased use of these highly effective long-acting reversible contraceptive (LARC) methods, contributed to the historically low teenage pregnancy rate in 2015 [24]. These observations support our recommendations to highlight LARC methods when discussing contraception with adolescents and young adults. (See "Pregnancy in adolescents", section on 'Epidemiology' and "Contraception: Overview of issues specific to adolescents", section on 'Long-acting reversible methods'.)

Updated US guidelines on HIV infection and pregnancy (November 2016)

The Department of Health and Human Services in the United States recently published updated guidelines on the evaluation and management of HIV-infected pregnant women to reduce the risk of perinatal transmission [25]. Preferred antiretroviral agents for initiation in pregnant women are now tenofovir-disoproxil-fumarate plus emtricitabine or lamivudine, abacavir-lamivudine, ritonavir-boosted atazanavir, ritonavir-boosted darunavir, and raltegravir. Other agents are not recommended for routine initiation in pregnant women because of limited data during pregnancy, but women who become pregnant while taking other commonly used agents can continue their regimen if they have achieved viral suppression. (See "Antiretroviral and intrapartum management of pregnant HIV-infected women and their infants in resource-rich settings", section on 'Antiretroviral selection and management'.)

Incidence of sexually transmitted infections in the United States (November 2016)

The total number of cases of chlamydia (over 1.5 million), gonorrhea (nearly 400,000), and syphilis (nearly 24,000) reported to the Centers for Disease Control and Prevention in the United States in 2015 was the highest ever recorded in a given year [26]. Chlamydia and gonorrhea continued to occur most commonly among 15 to 24 year olds, and men who have sex with men accounted for the majority of gonorrhea and primary/secondary syphilis cases. These surveillance data highlight the importance of sexually transmitted infection prevention efforts, screening, and treatment among at-risk individuals. (See "Epidemiology of Chlamydia trachomatis infections", section on 'Incidence' and "Epidemiology and pathogenesis of Neisseria gonorrhoeae infection", section on 'Incidence' and "Syphilis: Epidemiology, pathophysiology, and clinical manifestations in HIV-uninfected patients", section on 'Epidemiology' and "Screening for sexually transmitted infections".)


Safety of transvaginal mesh for stress urinary incontinence (February 2017)

Although relatively high complication rates have been reported when transvaginal mesh is used in pelvic organ prolapse surgery, this is not the case for female stress urinary incontinence (SUI) surgery. In a large cohort study comparing outcomes of mesh with non-mesh SUI procedures, the risk of immediate complications was approximately 50 percent lower in mesh-based procedures, with similar five-year efficacy and complication rates [27]. Transvaginal mesh continues to be the preferred surgical treatment for women with SUI. (See "Overview of transvaginal placement of mesh for prolapse and stress urinary incontinence", section on 'Choice of synthetic mesh or native tissue'.)

Guidance on hysteroscopic sterilization from the US FDA (November 2016)

Hysteroscopic placement of micro-inserts into the fallopian tubes is a minimally invasive approach to female sterilization; however, long-term complications are a concern. In October 2016 the US Food and Drug Administration (FDA) issued final guidance related to this procedure, recommending a boxed warning regarding potential adverse effects and the potential need for surgical removal to manage these effects [28]. The FDA also recommended a checklist highlighting key risk and benefit information to be reviewed and signed by the patient and physician and provided an example of a procedural consent form. (See "Hysteroscopic sterilization", section on 'Statements from regulatory organizations'.)

Outcomes of hysteroscopic versus laparoscopic sterilization (September 2016)

Female sterilization may be performed via laparoscopy or hysteroscopy, but few studies have compared the outcomes of these approaches. In a large retrospective study, hysteroscopic sterilization overall was associated with a higher pregnancy rate than laparoscopic sterilization (4.2 versus 3.7 percent at five years) [29]. However, women who completed the full protocol of hysteroscopic sterilization followed within six months by a hysterosalpingogram to confirm tubal occlusion had pregnancy rates similar to those who underwent a laparoscopic procedure. This suggests that the efficacy of these two procedures is comparable with ideal use, but hysteroscopic sterilization may have a higher failure rate with typical use. (See "Overview of female sterilization", section on 'Laparoscopy versus hysteroscopy'.)


Hysterectomy-corrected cervical cancer mortality rates and racial variation (February 2017)

Cervical cancer incidence and mortality rates are known to vary across racial groups in the United States but can be underestimated if data are not adjusted for prior hysterectomy. In a population-based study that corrected for the prevalence of hysterectomy, cervical cancer mortality in black women was more than twice that of white women from 2000 to 2012 (10.1 versus 4.7 per 100,000) [30]. These data add to the body of evidence showing a racial disparity in cervical cancer mortality and support the need for research to identify and overcome the factors that account for this disparity. (See "Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis", section on 'Incidence and mortality'.)

Risk of preterm delivery following loop electrosurgical excision procedure (LEEP) (November 2016)

Studies have consistently found an increased risk for preterm delivery in pregnancies conceived after cold knife conization, but data are mixed regarding the risk with laser conization and loop electrosurgical excision procedure (LEEP). In the largest study of pregnancy outcomes after treatment for cervical intraepithelial neoplasia (CIN), a Norwegian registry study of almost 10,000 births confirmed that prior treatment for CIN was associated with an increased risk of preterm birth compared with no prior treatment [31]. The strongest associations were for cold knife and laser conization, but a small increase in risk was also observed for LEEP. Women with CIN 2,3 who plan future childbearing should be counseled about the risks and benefits of both treatment and observation. (See "Cervical intraepithelial neoplasia: Reproductive effects of treatment", section on 'Risks of individual treatment methods'.)

Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer (October 2016)

In a phase III trial, niraparib was compared with placebo in approximately 550 patients with platinum-sensitive, recurrent ovarian cancer, stratified by germline mutation status [32]. Niraparib improved progression-free survival in all patient groups, although over a third experienced severe hematologic toxicity. In the absence of overall survival data, and given significant toxicity, the appropriate timeframe and strategy for further treatment (with niraparib as maintenance therapy, or with chemotherapy upon disease progression) is unclear. Niraparib remains investigational and should not be used outside of a clinical trial. (See "Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-sensitive disease".)


Safety of transvaginal mesh for stress urinary incontinence (February 2017)

Although relatively high complication rates have been reported when transvaginal mesh is used in pelvic organ prolapse surgery, this is not the case for female stress urinary incontinence (SUI) surgery. In a large cohort study comparing outcomes of mesh with non-mesh SUI procedures, the risk of immediate complications was approximately 50 percent lower in mesh-based procedures, with similar five-year efficacy and complication rates [27]. Transvaginal mesh continues to be the preferred surgical treatment for women with SUI. (See "Overview of transvaginal placement of mesh for prolapse and stress urinary incontinence", section on 'Choice of synthetic mesh or native tissue'.)

Cranberry products and urinary tract infection in women (October 2016)

Numerous clinical studies on the effects of cranberry products on recurrent urinary tract infection (UTI) in women have failed to clearly demonstrate a preventive benefit. In a year-long randomized trial among female nursing home residents, cranberry capsules similarly did not reduce adjusted rates of bacteriuria plus pyuria or symptomatic UTI compared with placebo [33]. While we do not suggest cranberry products to reduce the risk of recurrent UTI, there is likely little harmful effect. (See "Recurrent urinary tract infection in women", section on 'Cranberry products'.)

Treatment for refractory urgency urinary incontinence in women (October 2016)

Whether onabotulinumtoxinA (BoNT-A) or sacral neuromodulation (SNM) is the better treatment for women with refractory urgency urinary incontinence (UUI) is unclear. In a randomized trial directly comparing the two approaches, the BoNT-A group had greater reductions in daily UUI episodes and bothersome symptoms [34]. However, the small statistical differences may not be clinically significant, particularly since the risk of urinary tract infection increased. Thus, we believe that both treatments are reasonable treatment options for refractory UUI. (See "Use of botulinum toxin for treatment of non-neurogenic lower urinary tract conditions".)

Use of UpToDate is subject to the Subscription and License Agreement.


  1. Committee Opinion No. 688: Management of Suboptimally Dated Pregnancies. Obstet Gynecol 2017; 129:e29.
  2. Robinson CL, Romero JR, Kempe A, et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2017. MMWR Morb Mortal Wkly Rep 2017; 66:134.
  3. Kim DK, Riley LE, Harriman KH, et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2017. MMWR Morb Mortal Wkly Rep 2017; 66:136.
  4. Roberge S, Nicolaides K, Demers S, et al. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol 2017; 216:110.
  5. Meher S, Duley L, Hunter K, Askie L. Antiplatelet therapy before or after 16 weeks' gestation for preventing preeclampsia: an individual participant data meta-analysis. Am J Obstet Gynecol 2017; 216:121.
  6. Bisgaard H, Stokholm J, Chawes BL, et al. Fish Oil-Derived Fatty Acids in Pregnancy and Wheeze and Asthma in Offspring. N Engl J Med 2016; 375:2530.
  7. Viswanathan M, Treiman KA, Kish-Doto J, et al. Folic Acid Supplementation for the Prevention of Neural Tube Defects: An Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2017; 317:190.
  8. US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. Folic Acid Supplementation for the Prevention of Neural Tube Defects: US Preventive Services Task Force Recommendation Statement. JAMA 2017; 317:183.
  9. US Food and Drug Administration. Eating Fish: What Pregnant Women and Parents Should Know (Accessed on January 19, 2017).
  10. Committee Opinion No. 684: Delayed Umbilical Cord Clamping After Birth. Obstet Gynecol 2017; 129:e5.
  11. Brasil P, Pereira JP Jr, Moreira ME, et al. Zika Virus Infection in Pregnant Women in Rio de Janeiro. N Engl J Med 2016; 375:2321.
  12. Honein MA, Dawson AL, Petersen EE, et al. Birth Defects Among Fetuses and Infants of US Women With Evidence of Possible Zika Virus Infection During Pregnancy. JAMA 2017; 317:59.
  13. Brown QL, Sarvet AL, Shmulewitz D, et al. Trends in Marijuana Use Among Pregnant and Nonpregnant Reproductive-Aged Women, 2002-2014. JAMA 2017; 317:207.
  15. Moore CA, Staples JE, Dobyns WB, et al. Characterizing the Pattern of Anomalies in Congenital Zika Syndrome for Pediatric Clinicians. JAMA Pediatr 2016.
  16. Tita AT, Szychowski JM, Boggess K, et al. Adjunctive Azithromycin Prophylaxis for Cesarean Delivery. N Engl J Med 2016; 375:1231.
  17. Stewart ZA, Wilinska ME, Hartnell S, et al. Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. N Engl J Med 2016; 375:644.
  18. Ray JG, Vermeulen MJ, Bharatha A, et al. Association Between MRI Exposure During Pregnancy and Fetal and Childhood Outcomes. JAMA 2016; 316:952.
  19. US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. Serologic Screening for Genital Herpes Infection: US Preventive Services Task Force Recommendation Statement. JAMA 2016; 316:2525.
  20. (Accessed on November 18, 2016).
  21. Labrie F, Derogatis L, Archer DF, et al. Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. J Sex Med 2015; 12:2401.
  22. Fowler MG, Qin M, Fiscus SA, et al. Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention. N Engl J Med 2016; 375:1726.
  23. Usinger KM, Gola SB, Weis M, Smaldone A. Intrauterine Contraception Continuation in Adolescents and Young Women: A Systematic Review. J Pediatr Adolesc Gynecol 2016; 29:659.
  24. Martin JA, Hamilton BE, Osterman MJ, et al. Births: Final Data for 2015. Natl Vital Stat Rep 2017; 66:1.
  25. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. (Accessed on October 26, 2016).
  26. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance, 2015. Atlanta, GA: US Department of Health and Human Services; October 2016.
  27. Morling JR, McAllister DA, Agur W, et al. Adverse events after first, single, mesh and non-mesh surgical procedures for stress urinary incontinence and pelvic organ prolapse in Scotland, 1997-2016: a population-based cohort study. Lancet 2017; 389:629.
  28. (Accessed on November 02, 2016).
  29. Perkins RB, Morgan JR, Awosogba TP, et al. Gynecologic Outcomes After Hysteroscopic and Laparoscopic Sterilization Procedures. Obstet Gynecol 2016; 128:843.
  30. Beavis AL, Gravitt PE, Rositch AF. Hysterectomy-corrected cervical cancer mortality rates reveal a larger racial disparity in the United States. Cancer 2017.
  31. Bjørge T, Skare GB, Bjørge L, et al. Adverse Pregnancy Outcomes After Treatment for Cervical Intraepithelial Neoplasia. Obstet Gynecol 2016; 128:1265.
  32. Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med 2016; 375:2154.
  33. Juthani-Mehta M, Van Ness PH, Bianco L, et al. Effect of Cranberry Capsules on Bacteriuria Plus Pyuria Among Older Women in Nursing Homes: A Randomized Clinical Trial. JAMA 2016; 316:1879.
  34. Amundsen CL, Richter HE, Menefee SA, et al. OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial. JAMA 2016; 316:1366.
Topic 8350 Version 7086.0

Topic Outline



All topics are updated as new information becomes available. Our peer review process typically takes one to six weeks depending on the issue.